stockportfolio.pro
MeiraGTx Holdings plc (MGTX)
Healthcare · Biotechnology · NasdaqGS
MeiraGTx Holdings plc revenue & earnings — last 9 fiscal years
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $13.29M | $15.56M | $37.70M | $15.92M | $14.02M | $33.28M | $81.39M |
| Gross profit | — | — | — | — | — | — | $14.02M | $9.49M | $76.55M |
| Net income | $-31.04M | $-82.87M | $-54.75M | $-57.99M | $-79.56M | $-129.62M | $-84.03M | $-147.79M | $-114.20M |
| Net margin | — | — | -411.9% | -372.6% | -211.0% | -814.2% | -599.5% | -444.1% | -140.3% |
Source: MeiraGTx Holdings plc SEC filings (10-K).
Explore 9 years of MeiraGTx Holdings plc financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track MGTX in your portfolio →
MeiraGTx Holdings plc financial history by metric
About MeiraGTx Holdings plc
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
MeiraGTx Holdings plc — frequently asked questions
What is MeiraGTx Holdings plc's revenue?
MeiraGTx Holdings plc (MGTX) reported revenue of $81.39M for fiscal year 2025, up 144.6% from the prior year, according to its SEC filings.
Is MeiraGTx Holdings plc profitable?
No — MGTX reported a net loss of $-114.20M in fiscal 2025.
What is MGTX's P/E ratio?
MeiraGTx Holdings plc trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is MeiraGTx Holdings plc growing?
MGTX's revenue grew at roughly 39.2% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does MeiraGTx Holdings plc have?
As of fiscal year 2025, MGTX carried roughly $74.34M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is MeiraGTx Holdings plc's gross margin?
MGTX's gross margin was 94.0% in fiscal 2025 — gross profit of $76.55M on revenue of $81.39M.
What is MeiraGTx Holdings plc's market cap?
MeiraGTx Holdings plc (MGTX) has a market capitalization of about $883.03M, based on the latest data in our nightly-refreshed cache.
When does MeiraGTx Holdings plc's fiscal year end?
MGTX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from MeiraGTx Holdings plc's official SEC filings (10-K and 10-Q), covering 9 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.